Cargando…
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Human papillomaviruses (HPVs) are the most common sexually transmitted infections worldwide. Ninety percent of infected individuals clear the infection within two years; however, in the remaining 10% of infected individuals, the infection(s) persists and ultimately leads to cancers (anogenital cance...
Autores principales: | Yadav, Rashi, Zhai, Lukai, Tumban, Ebenezer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019592/ https://www.ncbi.nlm.nih.gov/pubmed/31877975 http://dx.doi.org/10.3390/v12010018 |
Ejemplares similares
-
Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51
por: Yadav, Rashi, et al.
Publicado: (2021) -
Virus-like Particle Vaccines and Platforms for Vaccine Development
por: Kheirvari, Milad, et al.
Publicado: (2023) -
Leishmaniasis Vaccine: Where are We Today?
por: Kedzierski, Lukasz
Publicado: (2010) -
Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018) -
Pathology of thymoma—where are we today?
por: Soomro, Irshad Nabi
Publicado: (2020)